Please login to the form below

Not currently logged in
Email:
Password:

MS symptom drug approved in US

The US FDA has approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis

The US Food and Drug Administration (FDA) has approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). Ampyra is the first therapy to be approved for this use.

The drug will be manufactured by Irish pharmaceutical company, Elan, and will be distributed in the US by Acorda Therapeutics.

Shane Cooke, executive vice president and head of Elan Drug Technologies said: "We wish to congratulate Acorda Therapeutics on the approval of Ampyra, which will bring a very important and much needed therapy to the market for MS sufferers."

Data from clinical trials shows that patients treated with Ampyra had faster walking speeds than those receiving a placebo. MS is a chronic disease affecting the central nervous system, often with disability affects. It is estimated to affect around 400,000 people in the US and 2.5 million people worldwide.

When given in doses higher than the recommended 10mg twice daily, Ampyra can cause seizures. Other reported side effects include insomnia, nausea, weakness and balance disorder.

25th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics